Search

Your search keyword '"Naik, Snehal"' showing total 125 results

Search Constraints

Start Over You searched for: Author "Naik, Snehal" Remove constraint Author: "Naik, Snehal"
125 results on '"Naik, Snehal"'

Search Results

9. 987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL

11. S714 Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-Label Extension

12. Challenges and Opportunities in IBD Clinical Trial Design

15. Real-time imaging of [beta]-catenin dynamics in cells and living mice

16. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

20. S0768 Early and Durable Symptom Control in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Etrasimod (APD334) in the Phase 2 OASIS Trial and Open Label Extension

21. Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS

22. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis

23. 764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study

24. 1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis

25. Tu1745 – Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations with Clinical Outcomes and Endoscopic Disease Activity in Patients with Ulcerative Colitis Receiving Induction Therapy with Etrasimod

26. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease

27. A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study: ACG Auxiliary Award (Member)

29. Mo1857 - Vedolizumab Levels During Induction are Associated with Long-Term Clinical and Endoscopic Remission in Patients with Inflammatory Bowel Disease

34. Higher Vedolizumab Levels are Associated with Deep Remission in Patients with Crohn's Disease and Ulcerative Colitis on Maintenance Therapy with Vedolizumab

37. Testing Serum Infliximab and Serum Antibodies to Infliximab with a Drug Tolerant Assay Has a Significant Effect on Clinical Decision Making in the Treatment of Patients with Inflammatory Bowel Diseases

40. RNA Interference Screen Identifies VEGFR1 as Potentially Synthetic Lethal to Aberrant Wnt/β-catenin Activation in Colon Cancer

47. Alzheimer's disease target selection

Catalog

Books, media, physical & digital resources